Replimune Group, Inc.

NASDAQ:REPL

Biotechnology

Healthcare
$19.81 +1.85%

+$0.19 today

Market cap
$1.88B
Beta
0.91
P/E (TTM)
-3.0
EPS (TTM)
-$3.42
52W Low $1.50High $13.24

Volume 2.13M

Average 7.51M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$192.25M

FY 2025 · Annual

Investing Cash Flow

-$23.80M

FY 2025 · Annual

Financing Cash Flow

$252.40M

FY 2025 · Annual

+1450.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Mar 2021
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
Net Income(80.87M)(118.04M)(174.28M)(215.79M)(247.3M)
Depreciation & Amortization1.71M2.15M2.45M2.66M3.5M
Deferred Income Tax0038K00
Stock-Based Compensation11.79M24.25M28.13M34.13M35.04M
Change in Working Capital3.51M7.24M15.12M5.48M24.08M
Accounts Receivables325K(247K)(61K)(1.92M)1.3M
Inventory0247K61K00
Accounts Payables(1.03M)1.12M1.98M(2.79M)9.94M
Other Working Capital4.22M6.12M13.14M10.19M12.84M
Other Non-Cash Items2.47M2.22M494K(11.94M)(7.58M)
Operating Cash Flow(61.39M)(82.18M)(128.05M)(185.47M)(192.25M)
Capital Expenditures(2.39M)(2.34M)(2.27M)(5.66M)(6.69M)
Acquisitions (Net)0(530)140.23K00
Purchases of Investments(392.43M)(255.72M)(583.41M)(489.52M)(403.59M)
Sales of Investments206.05M256.25M443.18M592.38M386.48M
Other Investing Activities0530(140.23K)00
Investing Cash Flow(188.78M)(1.81M)(142.5M)97.2M(23.8M)
Debt Repayment(10.15M)(264K)27.79M14.52M(599K)
Common Stock Issued286.11M6.86M187.29M1.76M155.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities96.5M096.22M097.27M
Financing Cash Flow372.46M6.6M311.3M16.28M252.4M
Effect of Forex Changes721K818K(109K)(86K)315K
Net Change in Cash123.02M(76.57M)40.64M(72.07M)36.67M
Free Cash Flow(63.78M)(84.52M)(130.32M)(191.13M)(198.94M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$247.3M
+ D&A$3.5M
+ Stock-Based Comp$35.0M
+ Deferred Tax$0
+ Working Capital$24.1M
- Other Non-Cash-$7.6M
= Operating Cash Flow-$192.3M
- Capex-$6.7M
= Free Cash Flow-$198.9M

Analysis

FY2025 free cash flow is -$198.9M. FCF conversion is 80.4% of net income. Operating cash flow was -$192.3M, with capex of -$6.7M. The largest bridge item is Stock-Based Comp at $35.0M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
4Statement of changes in beneficial ownershipNov 10, 2026
SC 13G/ASC 13G/A filingNov 9, 2026
10-Q/A10-Q/A filingNov 6, 2026
4Statement of changes in beneficial ownershipNov 3, 2026

Does REPL generate free cash flow?

Replimune Group, Inc. (REPL) generated -$198.94M of free cash flow in fiscal 2025.

How much operating cash flow does REPL produce?

Operating cash flow was -$192.25M, before capital expenditures of $6.69M.